Deep brain stimulation in neurological diseases and other pathologies

Marín-Márquez, Gerardo; Rangel, Carlos Castillo; Lara, Lázaro Salomón; Quesada, Luis Andrés Vega; Low, Carlos Daniel Borda; Abraham, Julian Eduardo Soto; Ávila, Genaro A. Coria; Denes, Jorge Manzo; Hernández, Leticia

doi:10.1016/j.neurop.2022.03.001

Cited by 12 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has even been suggested that some targeted therapies against motor manifestations, such as deep-brain-stimulation surgery of the subthalamic nucleus (STN-DBS) could represent a predisposing factor for the development of non-motor alterations, such as depression, impulsivity and decreased verbal fluency [ 5 , 117 ]. Regarding the presence of neuropsychiatric symptoms in PD, these are considered less of a determinant in the development of dementia in comparison with the influence of age and cognitive reserves [ 118 ].…”

Section: Discussionmentioning

confidence: 99%

“…The development and progression of PD manifestations have been mainly related to the significant decrease of the population of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNPc), in conjunction with the presence of Lewy bodies (LBs), which are intracytoplasmic inclusions, including insoluble and misfolded α-synuclein (α-syn) aggregates, considering LBs and the presence of α-syn as a pathognomonic molecular characteristic of PD [ 3 , 4 ]. Such alterations are usually more frequent in structures, such as the basal ganglia, the Locus Coeruleus, the raphe nuclei, the thalamus, the amygdala and the cerebellum [ 1 , 3 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…To this end, the multilevel study of PD is a useful tool in advancing the understanding of this disease and its relationship with neuroinflammation as well as the design of new treatment strategies [ 5 , 9 ]. That is why the aim of this article is to collect and present the most current advances regarding PD and neuroinflammation from a perspective that integrates multiple levels of study, from alterations in gene, molecular, cellular and tissue expression, to neuroanatomical alterations and clinical manifestations, related to the process of neuroinflammation in PD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Neuroinflammation in Parkinson’s Disease: From Gene to Clinic: A Systematic Review

Rangel

Marín-Márquez

Hernández-Contreras

et al. 2023

IJMS

View full text Add to dashboard Cite

Parkinson’s disease is a neurodegenerative disease whose progression and clinical characteristics have a close bidirectional and multilevel relationship with the process of neuroinflammation. In this context, it is necessary to understand the mechanisms involved in this neuroinflammation–PD link. This systematic search was, hereby, conducted with a focus on the four levels where alterations associated with neuroinflammation in PD have been described (genetic, cellular, histopathological and clinical-behavioral) by consulting the PubMed, Google Scholar, Scielo and Redalyc search engines, including clinical studies, review articles, book chapters and case studies. Initially, 585,772 articles were included, and, after applying the inclusion and exclusion criteria, 84 articles were obtained that contained information about the multilevel association of neuroinflammation with alterations in gene, molecular, cellular, tissue and neuroanatomical expression as well as clinical-behavioral manifestations in PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroinflammation in Parkinson’s Disease: From Gene to Clinic: A Systematic Review

Rangel

Marín-Márquez

Hernández-Contreras

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Many of these examples of neurotechnology are now well-established treatments used in routine clinical practice with some receiving approval by recognized regulatory authorities. DBS, for example, was approved by the US Food and Drug Administration in 1997 to treat essential tremor, in 2002 for Parkinson's disease, in 2003 for dystonia, and more recently in 2009 for obsessive-compulsive disorder ( 5 ).…”

Section: The Technology Revolution and Its Impact On Neurological Pra...mentioning

confidence: 99%

The grand challenge at the frontiers of neurotechnology and its emerging clinical applications

Bhidayasiri

2024

Front. Neurol.

View full text Add to dashboard Cite

“…Parkinson's disease (PD) is a complex neurodegenerative disease that manifests itself through a variety of motor (resting tremors, rigidity, bradykinesia, and postural instability) and non-motor symptoms 1 . Its incidence increases with age and due to this, manifestation of this condition among the population depends on this factor [2][3][4][5] . As far the non-motor manifestations during the course of PD, many patients experience neuropsychiatric disorders (depression, anxiety, sleep disturbances, psychosis, behavioral changes, etc.)…”

Section: Introductionmentioning

confidence: 99%

Main reasons for hospital admission in patients with ParkinsonÓ?s disease and their relationship with the days of hospitalization

Marín¹,

Torres-Pineda²,

Rangel³

et al. 2022

RMN

View full text Add to dashboard Cite

Objective: It is necessary to study the main comorbidities of Parkinson's disease that causes this increase in hospitalization.The aim of the study was to compare the mean days of hospital stay of patients with Parkinson's disease plus a comorbidity against the mean days of hospital stay without that comorbidity and to report those which were statistically significant. Methods: Taking patients with PD from "1 de octubre" Hospital, an observational, retrospective, cross-sectional, and analytical study was carried out in which the relationship of days of hospitalization with and without comorbidities was evaluated, finding which would be the comorbidities that were they become a factor of protection or risk of prolonging the hospital stay of patients with Parkinson's disease (PD) and thus suggest the priority of treating these conditions. Results: Of the 37 patients, 14 different comorbidities were found, of which hypothyroidism ( x = 2), acute myocardial infarction/dyslipidemia ( x = 4), and traumatic brain injury ( x = 4) present a decrease in the number of days hospitalized patients with respect to the mean of patients who do not have these comorbidities, in comparison, sacral ulcer ( x = 32.5) and pneumonia ( x = 31) show an increase in the days of hospitalization with respect to the mean. Conclusion: Fourteen comorbidities were found in PD. Patients with sacral ulcer and pneumonia are hospitalized for a longer time compared to the different comorbidities. It is recommended to pay special attention and care to prevent/treat these pathologies to reduce the number of days of hospitalization.

show abstract

Deep brain stimulation in neurological diseases and other pathologies

Cited by 12 publications

References 38 publications

Neuroinflammation in Parkinson’s Disease: From Gene to Clinic: A Systematic Review

Neuroinflammation in Parkinson’s Disease: From Gene to Clinic: A Systematic Review

The grand challenge at the frontiers of neurotechnology and its emerging clinical applications

Main reasons for hospital admission in patients with ParkinsonÓ?s disease and their relationship with the days of hospitalization

Contact Info

Product

Resources

About